Skip to main content
. 2011 May;9(3):219–225. doi: 10.1370/afm.1242

Table 2.

Odds of Receipt of Opioid Risk Reduction Strategies for Black vs White Patientsa

Additive Adjustment for Sets of Variables
Strategy Unadjusted Clusteringb Demographicsc Substance Abused Comorbiditiese Health Care Factorsf Practice Site
Urine drug testingg 1.63 (1.03–2.59) P=.04 1.53 (0.92–2.53) P=.10 1.44 (0.82–2.54) P=.21 1.45 (0.82–2.58) P=.20 1.54 (0.86–2.73) P=.15 1.56 (0.87–2.78) P=.14 1.41 (0.78–2.54) P=.26
Regular office visits 2.03 (1.65–2.49) P <.001 2.22 (1.71–2.87) P <.001 1.74 (1.28–2.38) P <.001 1.74 (1.28–2.38) P <.001 1.66 (1.21–2.28) P <.01 1.55 (1.10–2.19) P=.01 1.51 (1.06–2.14) P=.02
Restricted early refills 1.48 (1.17–1.87) P <.01 1.60 (1.22–2.10) P <.01 1.48 (1.06–2.08) P=.02 1.50 (1.07–2.10) P=.02 1.50 (1.01–2.11) P=.02 1.56 (1.06–2.31) P=.03 1.55 (1.03–2.32) P=.04

Note: Values are odds ratios (95% confidence intervals) and P values.

a Nonlinear mixed effect regression models adjusting additively for sets of patient, clinical, and health care variables.

b Clustering of patients within physician.

c Includes sex, age, median household income of neighborhood.

d Includes problem substance use (alcohol, nonopiates, and opioids), tobacco use.

e Mental health and medical comorbidities.

f Includes duration of long-term opioid treatment, appointment attendance rate, and primary care use category. Primary care use category was not included in the regular office visits models.

g Urine drug testing analysis excludes 2 practices that performed only 1 test or no tests in patients (n = 274 patients).